TOKYO, March 9 (Reuters) - Shares of Takeda Pharmaceutical (4502.T), Japan's biggest drugmaker, dived 13 percent on Monday, plunging by the daily limit on fears the replacement for its best-selling diabetes drug could be delayed by years in the United States.
